Mifepristone and Misoprostol for Fetal Demise (MIMID)
Anembryonic Pregnancy, Gestation Abnormality, Intrauterine Fetal Demise Term
About this trial
This is an interventional treatment trial for Anembryonic Pregnancy
Eligibility Criteria
Inclusion Criteria: healthy hemodynamically stable females with a non-viable pregnancy - Exclusion Criteria: orthostatic hypotension, contraindication to either mifepristone or misoprostol, treatment during current pregnancy to provide surgical or medical evacuation of the uterus, evidence of ovarian hyperstimulation syndrome, known or suspected pelvic infection,known or suspected clotting defect or receiving anticoagulants, cardiovascular disease, current breastfeeding, pregnancy with and IUD in situ, current participation in another clinical trial, prior participation in this trial, suspected or confirmed endometrial AV malformation, clinical indication requiring the karyotyping of products of conception
Sites / Locations
- Magee-Womens Hospital
Arms of the Study
Arm 1
Experimental
1
Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally